Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
FDA approves Guardant360 Liquid CDx with 100x larger genomic panel

FDA approves Guardant360 Liquid CDx with 100x larger genomic panel

New Capabilities

Blood-based cancer test now reads both genetic mutations and epigenetic patterns from a single draw

May 20th, 2026: Guardant360 Liquid CDx approved

Overview

For most patients with advanced cancer, picking the right targeted drug still starts with a tissue biopsy. On May 20, the FDA approved a blood test that reads 100 times more of the tumor's DNA than the previous version.

The new Guardant360 Liquid CDx, from Guardant Health, looks at both genetic mutations and epigenetic patterns in a single tube of blood. It returns results in about seven days. The seven companion diagnostic uses of its 2020 predecessor carry over to the new test.

Why it matters

If you or someone you love has advanced cancer, this test may replace a tissue biopsy and still pick the right targeted drug.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower

Key Indicators

100x
Wider genomic footprint
How much more of the tumor genome the new panel reads versus the 2020 Guardant360 CDx.
~7 days
Turnaround time
Roughly how fast oncologists get results after a single blood draw.
7
Companion diagnostic uses retained
Drug-pairing indications carried over from the original Guardant360 CDx.
$2.78B
U.S. liquid biopsy market, 2026
MarketsandMarkets and Towards Healthcare estimates for the current U.S. market.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Helmy Eltoukhy
Helmy Eltoukhy
Leading commercial rollout of Guardant360 Liquid CDx
 AmirAli Talasaz
AmirAli Talasaz
Leading R&D on the Smart Platform behind the new test

Organizations Involved

Guardant Health
Guardant Health
Cancer diagnostics company (Nasdaq: GH)
Maker of the newly approved Guardant360 Liquid CDx

Redwood City-based diagnostics company that builds blood-based cancer tests for treatment selection, residual disease monitoring, and screening.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Approved Guardant360 Liquid CDx on May 20, 2026

The federal agency that approves drugs, devices, and diagnostics for U.S. sale.

Timeline

June 2016 May 2026

5 events Latest: May 20th, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. Guardant360 Liquid CDx approved

    Latest Approval

    The FDA approved the new Guardant360 Liquid CDx, the largest liquid biopsy panel cleared to date. It reads 100 times the genome of the 2020 version and adds epigenomic profiling.

  2. Abbott closes $21B acquisition of Exact Sciences

    Market

    Abbott Laboratories absorbed Exact Sciences, consolidating one of Guardant's biggest competitors under a large-cap diagnostics owner.

  3. Shield approved for colorectal cancer screening

    Approval

    Guardant's Shield became the first liquid biopsy approved for cancer screening in average-risk adults.

  4. Original Guardant360 CDx approved

    Approval

    The FDA approved the first version of Guardant360 CDx as a companion diagnostic. FoundationOne Liquid CDx was approved the same month.

  5. First blood-based cancer genetic test approved

    Approval

    The FDA approved Roche's cobas EGFR Mutation Test v2 to detect EGFR mutations from plasma in non-small cell lung cancer.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

June 2016

First blood-based cancer genetic test (2016)

The FDA approved Roche's cobas EGFR Mutation Test v2 to detect EGFR mutations in plasma from non-small cell lung cancer patients. It looked at one gene. Until then, oncologists had to send tissue to a lab to test for the same mutation.

Then

Roche's test gave oncologists a way to pick EGFR-targeted drugs for lung cancer patients without a needle biopsy. Adoption was steady within lung cancer practices.

Now

It established the regulatory template the FDA would use to approve broader liquid biopsy panels four years later.

Why this matters now

The 2026 Guardant approval is the same regulatory category, scaled up by orders of magnitude. cobas read one gene; Guardant360 Liquid CDx now reads hundreds, plus epigenetic markers.

August 2020

Original Guardant360 CDx and FoundationOne Liquid CDx (2020)

Within a month of each other, the FDA approved the first two comprehensive liquid biopsy panels: Guardant360 CDx (August 7) and Foundation Medicine's FoundationOne Liquid CDx (August 26). Both let oncologists profile dozens of cancer-driver genes from a tube of blood.

Then

Liquid biopsy moved from niche to standard option for advanced cancer treatment selection. Insurance coverage followed in lung, breast, and colorectal cancer.

Now

The two tests defined the liquid biopsy companion diagnostic market through 2026. Guardant360 ran on roughly 80 genes; the new 2026 panel claims a footprint 100 times larger.

Why this matters now

The May 2026 approval is the first major upgrade to that 2020-era baseline. It's the same product family, six years later, with AI-driven sequencing and added epigenomic readouts.

July 2024

Shield approved for cancer screening (2024)

The FDA approved Guardant's Shield blood test for colorectal cancer screening in average-risk adults aged 45 and older. It was the first liquid biopsy approved for screening rather than treatment selection.

Then

Shield gave adults a blood-draw alternative to colonoscopy or stool-based testing. CMS issued coverage in 2024.

Now

Shield opened a second, larger market for liquid biopsy: people without cancer. Multi-cancer early detection tests from Grail, Exact Sciences (now Abbott), and others followed.

Why this matters now

Shield is Guardant's screening play; the new Guardant360 Liquid CDx is its treatment-selection play. Together they cover both ends of the cancer care path with blood draws.

Sources

(6)
Yahoo Finance Benzinga Conexiant Pathology U.S. Food and Drug Administration Market Minute PMC / NCBI